The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease

Paul Chr De Jong, Marinus A. Blankenstein, Johannes W R Nortier, Peter H Th J Slee, Joost Van De Ven, Joost M H H Van Gorp, Johannes R J Elbers, Margriet E I Schipper, Geert H. Blijham, Jos H H Thijssen, Qing Lu, Danijela Jelovac, Angela M. Brodie

Research output: Contribution to journalArticle

Abstract

Aromatase inhibitors are proving to be more effective than tamoxifen for postmenopausal patients with breast cancer. Estrogen concentrations in the breast are similar in both premenopausal and postmenopausal women, and several fold higher than circulating levels in postmenopausal women. In order to investigate the importance of intratumoral aromatase in stimulating the proliferation of the tumor, we used immunocytochemistry to determine the extent of aromatase expression in relationship to the response of the patient to aromatase inhibitor treatment. The relationship between positive staining for aromatase in the primary tumor and response to treatment with an aromatase inhibitor was investigated in a retrospective study of 102 patients with advanced breast cancer. Immunohistochemical staining using a monoclonal antibody against aromatase was performed on paraffin embedded tumor tissue. Response was evaluated using UICC criteria. Nine out of 13 patients with objective response to treatment stained positive and 49 of 89 patients with stable or progressive disease stained positive. No significant relationship between positive staining and objective response to treatment could be found. When patients with 'clinical benefit' (i.e. objective response plus prolonged stable disease of at least 6 months) were considered, also no relationship could be found. Further analysis of subgroups with positive hormone receptors, treatment with newer generation aromatase inhibitors, single metastatic site, non-visceral metastases and previous treatment only with tamoxifen did not show any relationship. Tumor aromatase expression did not correlate with response of patients with advanced breast cancer to aromatase inhibitor treatment. Most patients had relapsed from other treatments before receiving an aromatase inhibitor. It seems likely that many of these patients had tumors that may have progressed to hormone independence at this stage of the disease. Research in patients who have received treatment with aromatase inhibitors in earlier stages of disease (first line and adjuvant treatment) may provide further information on the relationship between tumor aromatase, steroid receptors and response to inhibitor treatment.

Original languageEnglish (US)
Pages (from-to)149-155
Number of pages7
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume87
Issue number2-3
DOIs
StatePublished - Nov 2003
Externally publishedYes

Fingerprint

Aromatase Inhibitors
Aromatase
Tumors
Breast Neoplasms
Tamoxifen
Therapeutics
Neoplasms
Hormones
Staining and Labeling
Steroid Receptors
Paraffin
Estrogens
Monoclonal Antibodies
Tissue
Breast
Retrospective Studies
Immunohistochemistry
Neoplasm Metastasis

Keywords

  • Aromatase
  • Aromatase immunohistochemical staining
  • Aromatase inhibitors
  • Aromatase monoclonal antibody
  • Breast cancer
  • Hormonal therapy

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

De Jong, P. C., Blankenstein, M. A., Nortier, J. W. R., Slee, P. H. T. J., Van De Ven, J., Van Gorp, J. M. H. H., ... Brodie, A. M. (2003). The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease. Journal of Steroid Biochemistry and Molecular Biology, 87(2-3), 149-155. https://doi.org/10.1016/j.jsbmb.2003.09.012

The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease. / De Jong, Paul Chr; Blankenstein, Marinus A.; Nortier, Johannes W R; Slee, Peter H Th J; Van De Ven, Joost; Van Gorp, Joost M H H; Elbers, Johannes R J; Schipper, Margriet E I; Blijham, Geert H.; Thijssen, Jos H H; Lu, Qing; Jelovac, Danijela; Brodie, Angela M.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 87, No. 2-3, 11.2003, p. 149-155.

Research output: Contribution to journalArticle

De Jong, PC, Blankenstein, MA, Nortier, JWR, Slee, PHTJ, Van De Ven, J, Van Gorp, JMHH, Elbers, JRJ, Schipper, MEI, Blijham, GH, Thijssen, JHH, Lu, Q, Jelovac, D & Brodie, AM 2003, 'The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease', Journal of Steroid Biochemistry and Molecular Biology, vol. 87, no. 2-3, pp. 149-155. https://doi.org/10.1016/j.jsbmb.2003.09.012
De Jong, Paul Chr ; Blankenstein, Marinus A. ; Nortier, Johannes W R ; Slee, Peter H Th J ; Van De Ven, Joost ; Van Gorp, Joost M H H ; Elbers, Johannes R J ; Schipper, Margriet E I ; Blijham, Geert H. ; Thijssen, Jos H H ; Lu, Qing ; Jelovac, Danijela ; Brodie, Angela M. / The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease. In: Journal of Steroid Biochemistry and Molecular Biology. 2003 ; Vol. 87, No. 2-3. pp. 149-155.
@article{5c696e87ba114f0681fb3c18f8b6eeb7,
title = "The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease",
abstract = "Aromatase inhibitors are proving to be more effective than tamoxifen for postmenopausal patients with breast cancer. Estrogen concentrations in the breast are similar in both premenopausal and postmenopausal women, and several fold higher than circulating levels in postmenopausal women. In order to investigate the importance of intratumoral aromatase in stimulating the proliferation of the tumor, we used immunocytochemistry to determine the extent of aromatase expression in relationship to the response of the patient to aromatase inhibitor treatment. The relationship between positive staining for aromatase in the primary tumor and response to treatment with an aromatase inhibitor was investigated in a retrospective study of 102 patients with advanced breast cancer. Immunohistochemical staining using a monoclonal antibody against aromatase was performed on paraffin embedded tumor tissue. Response was evaluated using UICC criteria. Nine out of 13 patients with objective response to treatment stained positive and 49 of 89 patients with stable or progressive disease stained positive. No significant relationship between positive staining and objective response to treatment could be found. When patients with 'clinical benefit' (i.e. objective response plus prolonged stable disease of at least 6 months) were considered, also no relationship could be found. Further analysis of subgroups with positive hormone receptors, treatment with newer generation aromatase inhibitors, single metastatic site, non-visceral metastases and previous treatment only with tamoxifen did not show any relationship. Tumor aromatase expression did not correlate with response of patients with advanced breast cancer to aromatase inhibitor treatment. Most patients had relapsed from other treatments before receiving an aromatase inhibitor. It seems likely that many of these patients had tumors that may have progressed to hormone independence at this stage of the disease. Research in patients who have received treatment with aromatase inhibitors in earlier stages of disease (first line and adjuvant treatment) may provide further information on the relationship between tumor aromatase, steroid receptors and response to inhibitor treatment.",
keywords = "Aromatase, Aromatase immunohistochemical staining, Aromatase inhibitors, Aromatase monoclonal antibody, Breast cancer, Hormonal therapy",
author = "{De Jong}, {Paul Chr} and Blankenstein, {Marinus A.} and Nortier, {Johannes W R} and Slee, {Peter H Th J} and {Van De Ven}, Joost and {Van Gorp}, {Joost M H H} and Elbers, {Johannes R J} and Schipper, {Margriet E I} and Blijham, {Geert H.} and Thijssen, {Jos H H} and Qing Lu and Danijela Jelovac and Brodie, {Angela M.}",
year = "2003",
month = "11",
doi = "10.1016/j.jsbmb.2003.09.012",
language = "English (US)",
volume = "87",
pages = "149--155",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "2-3",

}

TY - JOUR

T1 - The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease

AU - De Jong, Paul Chr

AU - Blankenstein, Marinus A.

AU - Nortier, Johannes W R

AU - Slee, Peter H Th J

AU - Van De Ven, Joost

AU - Van Gorp, Joost M H H

AU - Elbers, Johannes R J

AU - Schipper, Margriet E I

AU - Blijham, Geert H.

AU - Thijssen, Jos H H

AU - Lu, Qing

AU - Jelovac, Danijela

AU - Brodie, Angela M.

PY - 2003/11

Y1 - 2003/11

N2 - Aromatase inhibitors are proving to be more effective than tamoxifen for postmenopausal patients with breast cancer. Estrogen concentrations in the breast are similar in both premenopausal and postmenopausal women, and several fold higher than circulating levels in postmenopausal women. In order to investigate the importance of intratumoral aromatase in stimulating the proliferation of the tumor, we used immunocytochemistry to determine the extent of aromatase expression in relationship to the response of the patient to aromatase inhibitor treatment. The relationship between positive staining for aromatase in the primary tumor and response to treatment with an aromatase inhibitor was investigated in a retrospective study of 102 patients with advanced breast cancer. Immunohistochemical staining using a monoclonal antibody against aromatase was performed on paraffin embedded tumor tissue. Response was evaluated using UICC criteria. Nine out of 13 patients with objective response to treatment stained positive and 49 of 89 patients with stable or progressive disease stained positive. No significant relationship between positive staining and objective response to treatment could be found. When patients with 'clinical benefit' (i.e. objective response plus prolonged stable disease of at least 6 months) were considered, also no relationship could be found. Further analysis of subgroups with positive hormone receptors, treatment with newer generation aromatase inhibitors, single metastatic site, non-visceral metastases and previous treatment only with tamoxifen did not show any relationship. Tumor aromatase expression did not correlate with response of patients with advanced breast cancer to aromatase inhibitor treatment. Most patients had relapsed from other treatments before receiving an aromatase inhibitor. It seems likely that many of these patients had tumors that may have progressed to hormone independence at this stage of the disease. Research in patients who have received treatment with aromatase inhibitors in earlier stages of disease (first line and adjuvant treatment) may provide further information on the relationship between tumor aromatase, steroid receptors and response to inhibitor treatment.

AB - Aromatase inhibitors are proving to be more effective than tamoxifen for postmenopausal patients with breast cancer. Estrogen concentrations in the breast are similar in both premenopausal and postmenopausal women, and several fold higher than circulating levels in postmenopausal women. In order to investigate the importance of intratumoral aromatase in stimulating the proliferation of the tumor, we used immunocytochemistry to determine the extent of aromatase expression in relationship to the response of the patient to aromatase inhibitor treatment. The relationship between positive staining for aromatase in the primary tumor and response to treatment with an aromatase inhibitor was investigated in a retrospective study of 102 patients with advanced breast cancer. Immunohistochemical staining using a monoclonal antibody against aromatase was performed on paraffin embedded tumor tissue. Response was evaluated using UICC criteria. Nine out of 13 patients with objective response to treatment stained positive and 49 of 89 patients with stable or progressive disease stained positive. No significant relationship between positive staining and objective response to treatment could be found. When patients with 'clinical benefit' (i.e. objective response plus prolonged stable disease of at least 6 months) were considered, also no relationship could be found. Further analysis of subgroups with positive hormone receptors, treatment with newer generation aromatase inhibitors, single metastatic site, non-visceral metastases and previous treatment only with tamoxifen did not show any relationship. Tumor aromatase expression did not correlate with response of patients with advanced breast cancer to aromatase inhibitor treatment. Most patients had relapsed from other treatments before receiving an aromatase inhibitor. It seems likely that many of these patients had tumors that may have progressed to hormone independence at this stage of the disease. Research in patients who have received treatment with aromatase inhibitors in earlier stages of disease (first line and adjuvant treatment) may provide further information on the relationship between tumor aromatase, steroid receptors and response to inhibitor treatment.

KW - Aromatase

KW - Aromatase immunohistochemical staining

KW - Aromatase inhibitors

KW - Aromatase monoclonal antibody

KW - Breast cancer

KW - Hormonal therapy

UR - http://www.scopus.com/inward/record.url?scp=10744227481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744227481&partnerID=8YFLogxK

U2 - 10.1016/j.jsbmb.2003.09.012

DO - 10.1016/j.jsbmb.2003.09.012

M3 - Article

C2 - 14672735

AN - SCOPUS:10744227481

VL - 87

SP - 149

EP - 155

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 2-3

ER -